
DNA
Ginkgo Bioworks Holdings Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.4397
Open
9.970
VWAP
10.15
Vol
1.55M
Mkt Cap
562.54M
Low
9.780
Amount
15.75M
EV/EBITDA(TTM)
--
Total Shares
2.21B
EV
45.62M
EV/OCF(TTM)
--
P/S(TTM)
2.26
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
40.91M
-27.21%
--
--
43.41M
-51.26%
--
--
44.20M
+0.81%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Ginkgo Bioworks Holdings, Inc. (DNA) for FY2025, with the revenue forecasts being adjusted by 3.26% over the past three months. During the same period, the stock price has changed by 38.01%.
Revenue Estimates for FY2025
Revise Upward

+3.26%
In Past 3 Month
Stock Price
Go Up

+38.01%
In Past 3 Month
5 Analyst Rating

-11.15% Downside
Wall Street analysts forecast DNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 9.00 USD with a low forecast of 6.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
3 Sell
Moderate Sell

-11.15% Downside
Current: 10.130

Low
6.00
Averages
9.00
High
12.00

-11.15% Downside
Current: 10.130

Low
6.00
Averages
9.00
High
12.00
TD Cowen
Brendan Smith
Strong Buy
Maintains
$3 → $10
2024-09-20
Reason
TD Cowen
Brendan Smith
Price Target
$3 → $10
2024-09-20
Maintains
Strong Buy
Reason
BTIG
Mark Massaro
Strong Sell
Maintains
$0.2 → $7
2024-08-23
Reason
BTIG
Mark Massaro
Price Target
$0.2 → $7
2024-08-23
Maintains
Strong Sell
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Ginkgo Bioworks Holdings Inc (DNA.N) is -1.68, compared to its 5-year average forward P/E of -16.44. For a more detailed relative valuation and DCF analysis to assess Ginkgo Bioworks Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-16.44
Current PE
-1.68
Overvalued PE
14.04
Undervalued PE
-46.93
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-19.09
Current EV/EBITDA
-2.95
Overvalued EV/EBITDA
16.90
Undervalued EV/EBITDA
-55.08
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
13.64
Current PS
3.38
Overvalued PS
28.58
Undervalued PS
-1.30
Financials
Annual
Quarterly
FY2025Q1
YoY :
+27.34%
48.32M
Total Revenue
FY2025Q1
YoY :
-46.70%
-84.61M
Operating Profit
FY2025Q1
YoY :
-45.18%
-90.96M
Net Income after Tax
FY2025Q1
YoY :
-49.24%
-1.68
EPS - Diluted
FY2025Q1
YoY :
-38.37%
-59.14M
Free Cash Flow
FY2025Q1
YoY :
-0.90%
75.07
Gross Profit Margin - %
FY2025Q1
YoY :
-5.81%
-145.44
FCF Margin - %
FY2025Q1
YoY :
-56.95%
-188.25
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
5.4K
USD
1
3-6
Months
40.4K
USD
6
6-9
Months
34.2K
USD
6
0-12
Months
21.8K
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
281.0K
Volume
1
6-9
Months
287.5K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
1.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
5.4K
USD
1
3-6
Months
40.4K
USD
6
6-9
Months
34.2K
USD
6
0-12
Months
21.8K
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DNA News & Events
Events Timeline
2025-07-07 (ET)
2025-07-07
12:02:07
Ginkgo Bioworks falls -10.2%

2025-06-30 (ET)
2025-06-30
12:00:38
Ginkgo Bioworks rises 17.0%

2025-06-11 (ET)
2025-06-11
09:47:22
Ginkgo Bioworks rises 5.4%

Sign Up For More Events
Sign Up For More Events
News
5.0
07-17PRnewswireGinkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors
2.0
07-17NASDAQ.COMGinkgo Bioworks Holdings, Inc. (DNA) Outperforms Broader Market: What You Need to Know
2.0
07-11NASDAQ.COMGinkgo Bioworks Holdings, Inc. (DNA) Stock Sinks As Market Gains: Here's Why
Sign Up For More News
People Also Watch

EXP
Eagle Materials Inc
215.120
USD
-0.41%

CVS
CVS Health Corp
61.960
USD
-2.12%

PYPL
PayPal Holdings Inc
74.170
USD
+0.42%

ROKU
Roku Inc
93.290
USD
+2.40%

DELL
Dell Technologies Inc
131.240
USD
+5.94%

GM
General Motors Co
53.220
USD
+0.02%

BNGO
Bionano Genomics Inc
3.430
USD
+0.88%

F
Ford Motor Co
11.160
USD
+0.09%

PPC
Pilgrims Pride Corp
44.940
USD
-0.27%

GAME
GameSquare Holdings Inc
1.520
USD
-5.59%
FAQ

What is Ginkgo Bioworks Holdings Inc (DNA) stock price today?
The current price of DNA is 10.13 USD — it has increased 3.79 % in the last trading day.

What is Ginkgo Bioworks Holdings Inc (DNA)'s business?

What is the price predicton of DNA Stock?

What is Ginkgo Bioworks Holdings Inc (DNA)'s revenue for the last quarter?

What is Ginkgo Bioworks Holdings Inc (DNA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Ginkgo Bioworks Holdings Inc (DNA)'s fundamentals?

How many employees does Ginkgo Bioworks Holdings Inc (DNA). have?
